

RECEIVED

APR 18 2001

TECH CENTER 1600/2900

REMARKS

The above-outlined amendments are necessary in order to bring the Sequence Listing in conformity with 37 C.F.R. §1.821. SEQ ID NO:1, as originally filed, was directed to the HP1/2 antibody heavy chain variable region nucleic acid sequence wherein the first codon corresponds to either amino acid Glu or Gln (as stated in the "Feature Description" for SEQ ID NO:1 of the Sequence Listing filed in the prior application, USSN 08/456,193, filed May 31, 1995). The first amino acid position was not included in the sequence of SEQ ID NO:1 itself, which began with the second residue (Val). SEQ ID NO:2, as originally filed, is the corresponding amino acid sequence beginning with position 2. SEQ ID NO:1 and SEQ ID NO:2, as originally filed in USSN 08/456,193, both started with amino acid Val at position 2.

In order to satisfy requirements of 37 C.F.R. §1.821, SEQ ID NO:1 was amended to start at position 1 with the following nucleotide sequence "GAR" (R is the accepted designation for nucleotides A or G pursuant to 37 C.F.R. §1.822(b)(1)) which corresponds to amino acid Glu. SEQ ID NO:2 was accordingly amended to start with amino acid Glu at position 1.

In addition, new SEQ ID NO:12 was created which is identical to SEQ ID NO:1, as filed, except at position 1 it has the following nucleotide sequence "CAR" which corresponds to amino acid Gln. New SEQ ID NO:13 was created which is identical to SEQ ID NO:2, as filed, except at position 1 it has the amino acid Gln.

No new matter has been added.

Applicants respectfully request entry of the above-outlined amendments in order to bring the Sequence Listing in conformity with 37 C.F.R. §1.821.

Applicant : Lobb et al.
Serial No. : 09/251,073
Filed : February 16, 1999
Page : 4

Attorney's Docket No.: 10274-003003

Attached is a marked-up version of the changes being made by the current amendment.

Please apply any other charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: April 10, 2001

Diane Celler Reg No 46,635
for Louis Myers
Reg. No. 35,965

Fish & Richardson P.C.
225 Franklin Street
Boston, MA 02110-2804
Telephone: (617) 542-5070
Facsimile: (617) 542-8906

20239299.doc

Applicant : Lobb et al.
Serial No. : 09/251,073
Filed : February 16, 1999
Page : 5

Attorney's Docket No.: 10274-003003

RECEIVED

APR 18 2001

TECH CENTER 1600/2900

Version with markings to show changes made

In the specification:

Paragraph beginning at page 6, line 21 has been amended as follows:

Several anti-VLA-4 monoclonal antibodies have been previously described (see, e.g., Sanchez-Madrid et al., 1986 [16]; Hemler et al. (1987) [17]; Pulido et al. (1991) [19]). For the experiments herein, an anti-VLA-4 monoclonal antibody designated HP1/2 (obtained from Biogen, Inc., Cambridge, MA) was used. The variable regions of the heavy and light chains of the anti-VLA-4 antibody HP1/2 have been cloned, sequenced and expressed in combination with constant regions of human immunoglobulin heavy and light chains. Such chimeric HP1/2 antibody is similar in specificity and potency to the murine HP1/2 antibody, and may be useful in methods of treatment according to the present invention. Similarly, humanized recombinant anti-VLA-4 antibodies may be useful in these methods. The HP1/2 V_H DNA sequence and its translated amino acid sequences are set forth in SEQ ID NO:1 or SEQ ID NO:12, and SEQ ID NO:2 or SEQ ID NO:13, respectively. The HP1/2 V_K DNA sequence and its translated amino acid sequence are set forth in SEQ ID NO:3 and SEQ ID NO:4, respectively.